# Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

> clinical trial · VERIFIED · 2026-08-24

Status: RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Prostate Cancer Metastatic

- Company: Merck Sharp & Dohme LLC
- Sector: therapeutics
- Primary source: https://clinicaltrials.gov/study/NCT06136624

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.